Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;25(9):2647-2664.
doi: 10.1007/s12094-023-03215-4. Epub 2023 Jun 16.

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

Francisco Ayala de la Peña  1 , Silvia Antolín Novoa  2 , Joaquín Gavilá Gregori  3 , Lucía González Cortijo  4 , Fernando Henao Carrasco  5 , María Teresa Martínez Martínez  6 , Cristina Morales Estévez  7 , Agostina Stradella  8 , María Jesús Vidal Losada  9 , Eva Ciruelos  10
Affiliations

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

Francisco Ayala de la Peña et al. Clin Transl Oncol. 2023 Sep.

Erratum in

  • Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022).
    Ayala de la Peña F, Antolín Novoa S, Gavilá Gregori J, González Cortijo L, Henao Carrasco F, Martínez Martínez MT, Morales Estévez C, Stradella A, Vidal Losada MJ, Ciruelos E. Ayala de la Peña F, et al. Clin Transl Oncol. 2024 Feb;26(2):555-556. doi: 10.1007/s12094-023-03334-y. Clin Transl Oncol. 2024. PMID: 37902930 Free PMC article. No abstract available.

Abstract

Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is rapidly increasing. Thanks to the screening programs in place, nearly 90% of breast cancer cases are detected in early and potentially curable stages, despite the COVID-19 pandemic possibly having impacted these numbers (not yet quantified). In recent years, locoregional and systemic therapies are increasingly being directed by new diagnostic tools that have improved the balance between toxicity and clinical benefit. New therapeutic strategies, such as immunotherapy, targeted drugs, and antibody-drug conjugates have also improved outcomes in some patient subgroups. This clinical practice guideline is based on a systematic review of relevant studies and on the consensus of experts from GEICAM, SOLTI, and SEOM.

Keywords: Adjuvant; Early breast cancer; Follow-up; Neoadjuvant.

PubMed Disclaimer

Conflict of interest statement

FAP reports Speaker from Astra Zeneca, Novartis, Lilly, Sanofi and Daichii Sankyo; Speaker and Others from Celgene, Eisai and Pierre Fabre; Advisory Board—Speaker—Other from Pfizer and Roche; Advisory Board from Seagen; Other from MSD. JGG reports Advisory Board—Speaker—Non-financial Support from Daiichi Sankyo, AstraZeneca, Novartis, Roche and Pfizer; Speaker from lilly. FH reports Advisory from AstraZeneca, Daiichi-Sankyo, Novartis, Pfizer, Lilly and Roche. EC reports Advisory Board—Speaker from Roche, Lilly, Pfizer, AstraZeneca, Daichii Sankyo, Novartis, MSD and Gilead; Advisory Board from Reveal Genomics. MJVL, SAN, AS, LGC, CME, TMM have nothing to disclose.

Figures

Fig. 1
Fig. 1
HR positive/HER2-negative early breast cancer algorithm. AI: aromatase inhibitors; BCS: breast conservation; CT: chemotherapy; ET: endocrine therapy; N: axillar node; OFS: ovarian function suppression; y: years; +:  positive; -: negative. *Consider in premenopausal patients with luminal A-like tumors and no indication for chemotherapy, who are not candidates for optimal surgery, OFS plus an aromatase inhibitor can be considered
Fig. 2
Fig. 2
HER2-positive early breast cancer algorithm. CT: chemotherapy. pCR: pathologic complete response. (1) This treatment is still awaiting financial approval from the health authorities in Spain
Fig. 3
Fig. 3
Triple negative early breast cancer algorithm. CT: chemotherapy. pCR: pathologic complete response
See this image and copyright information in PMC

Comment in

  • Just medical oncology guidelines….
    Pardo García R, Piñero Madrona A, Algara López M, Bernet Vegué L, Eraso Urien A. Pardo García R, et al. Clin Transl Oncol. 2023 Nov;25(11):3319-3320. doi: 10.1007/s12094-023-03272-9. Epub 2023 Jul 12. Clin Transl Oncol. 2023. PMID: 37438652 No abstract available.

References

    1. Sociedad Española de Oncología Médica (SEOM), Red Española de Registros del Cáncer (REDECAN). Las cifras del cáncer en España (2022). In: https://seom.org/images/LAS_CIFRAS_DEL_CANCER_EN_ESPANA_2022.pdf. Accessed 10 Nov 2022.
    1. Bosch G, Posso M, Louro J, Roman M, Porta M, Castells X, et al. Impact of the COVID-19 pandemic on breast cancer screening indicators in a Spanish population-based program: a cohort study. Elife. 2022;11:1–16. doi: 10.7554/eLife.77434. - DOI - PMC - PubMed
    1. Khan AR, Khan S, Zimmerman V, Baddour LM, Tleyjeh IM. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis. 2010;51:1147–1156. doi: 10.1086/656735. - DOI - PubMed
    1. Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast cancer-major changes in the american joint committee on cancer eighth edition cancer staging manual. Cancer J Clin. 2017;67:290–303. doi: 10.3322/caac.21393. - DOI - PubMed
    1. Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition–summary document. Ann. Oncol. 2007;19:614–22. doi: 10.1093/annonc/mdm481. - DOI - PubMed

Publication types